Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1040-1043, 2005; 10.1373/clinchem.2004.045633
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Danilov, S. M.
Right arrow Articles by Albrecht, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Danilov, S. M.
Right arrow Articles by Albrecht, R. F.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Other Areas of Clinical Chemistry
(Clinical Chemistry. 2005;51:1040-1043.)
© 2005 American Association for Clinical Chemistry, Inc.

Technical Briefs

Detection of Mutated Angiotensin I-Converting Enzyme by Serum/Plasma Analysis Using a Pair of Monoclonal Antibodies

Sergei M. Danilov1,a, Jaap Deinum2, Irina V. Balyasnikova1, Zhu-Li Sun1, Cornelis Kramers2,3,4, Carla E.M. Hollak5 and Ronald F. Albrecht1

1 Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL; Departments of2 Medicine, 3 Pharmacology/Toxicology, and4 Internal Medicine, University Medical Center, Nijmegen, The Netherlands;5 Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands;

aaddress correspondence to this author at: Anesthesiology Research Center, University of Illinois at Chicago, 1819 W. Polk St. (M/C 519), Chicago, IL 60612; fax 312-996-9680, e-mail danilov@uic.edu

The first 300 words of the full text of this article appear below.

Angiotensin I-converting enzyme (ACE; CD143) is a Zn2+ carboxydipeptidase that plays a key role in the regulation of blood pressure and in the development of vascular pathology and remodeling (1)(2)(3). ACE is constitutively expressed on the surface of endothelial cells, macrophages, dendritic cells, and various other cell types (4)(5). Somatic ACE contains two homologous domains, N- and C-terminal, each with a catalytic center (2)(6). ACE has been accepted as a CD marker, CD143 (4)(6).

Soluble serum ACE originates from endothelial cells by proteolytic cleavage by an unidentified protease of the Arg1203–Ser1204 peptide bond in the stalk region near the C-terminal transmembrane sequence of the ACE molecule (7)(8)(9)(10)(11). At physiologic conditions, the concentration of ACE in blood is very stable (12), whereas the ACE concentration in serum is often significantly increased in granulomatous diseases (in particular, sarcoidosis) or Gaucher disease (13)(14)(15)(16)(17)(18).

We described a Pro1199Leu mutation, located in the juxtamembrane stalk region of ACE (19)(20), that explained a considerable familial increase in blood ACE activity in individuals from several Dutch families (19). The same phenotype and autosomal-dominant inheritance pattern have been described in Japan (21) and Italy(22). Despite the fact that patients with this mutation at first scrutiny do not have clinical abnormalities (19), the finding of increased ACE has led to confusion for treating physicians (23)(24).

We recently observed reduced binding of soluble ACE in Dutch patients with a Pro1199Leu substitution detected by a new monoclonal antibody (mAb), 1B3, which recognizes . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.